Recent research suggests a possible increased risk of serious eye conditions, such as non-arteritic anterior ischaemic optic ...

The risk of new-onset diabetic retinopathy (DR) increased slightly, but significantly, in patients taking GLP-1 receptor ...

A real-world study found that semaglutide prescriptions were associated with improvements in weight, blood pressure, and ...

In this cohort study of adults prescribed semaglutide, initiation was associated with reductions in weight and cardiovascular risk ...

A popular drug used for diabetes and weight loss may also help protect the brain. That’s the key message from a new study ...

A study has found that prescribing semaglutide in everyday clinical settings led to modest but meaningful improvements in cardiovascular risk alongside a rise in non-drug healthcare costs. The study, ...

In this cohort study of adults prescribed semaglutide, initiation was associated with reductions in weight and cardiovascular risk factors but increases in health care expenditures, excluding ...

Semaglutide is the active ingredient in the weight loss medication Wegovy and the diabetes drugs Ozempic and Rybelsus, which ...

NAION is the second most frequent cause of vision loss due to optic nerve damage, with advanced age and long-standing type 2 ...

Results confirm previous findings that nonarteritic anterior ischemic optic neuropathy (NAION) was more likely in those who ...

The risk for major adverse cardiovascular events decreased with tirzepatide vs. liraglutide and semaglutide in patients with ...

Once-weekly semaglutide significantly slowed epigenetic aging in adults with HIV-associated lipohypertrophy, as measured by ...